Global Bridges at Mayo Clinic and Pfizer Global Medical Grants
Quality Improvement Request for Proposals (RFP)
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis

Date RFP Issued: 18 March 2024

Background and Purpose of this RFP
Amyloidosis is often misdiagnosed. For example, it is estimated that the correct diagnosis of TTR amyloidosis is delayed by years, in part because it is a multisystemic disorder. Our goal is to help accelerate this patient journey by supporting capacity building programs.

In recent years, Global Bridges at Mayo Clinic and Pfizer Global Medical Grants have supported independent projects focused on raising awareness and closing knowledge gaps to reduce the time it takes for patients to be correctly diagnosed and make treatment more accessible, while supporting the development of a global network of TTR amyloidosis experts. Expanding the community of practice will help decrease the distance patients need to travel to be diagnosed, although valuable guidance may still be obtained from experienced centers further from home. This RFP is a continuation of this program.

It is not our intent to support research projects. Any research projects will be considered out of scope for this project. Examples of out-of-scope projects include clinical research projects, basic science research, prevalence studies, registry development, health services research and outcomes research.

Geographic Scope: Global (not including the United States)

Funding and Administration of Projects
Project proposals will be reviewed and recommended by an expert advisory panel. Projects selected for funding will be funded directly by Pfizer Inc.

Operational and technical support for funded projects will be provided by Mayo Clinic.

Applicant Eligibility
Applications are invited from institutions, organizations or associations, e.g. professional schools, hospitals, healthcare systems, universities, patient advocacy groups, professional associations, government agencies

Grants can only be awarded to organizations, not individuals or medical practice groups.

Clinical Area
TTR Amyloidosis (any organ system)
Characteristics of a Successful Proposal

In order to increase the capacity of the health care system to provide more timely diagnosis and appropriate treatment to TTR amyloidosis sufferers in any organ, we are interested in receiving proposals that:

- Reduce the time to correct diagnosis, among a broad audience of health care professionals, including increasing coordination across specialties; AND
- Build on evidence and international best practice; AND
- Include a robust and well-defined plan for evaluation and dissemination; AND
- Support the development of a global network of health care professionals capable of diagnosing and treating TTR amyloidosis, AND
- Support the development of a global network of TTR amyloidosis experts
- Include a plan to sustain the project beyond the period of funding.

Out of Scope of this Call

It is not our intent to support research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Additional examples of out-of-scope projects include clinical research projects, basic science research, prevalence studies, registry development, health services research and outcomes research.

Funding Available/Maximum Award Levels

Total funding available for this RFP is US $225,000. We anticipate funding 3 projects.

How to Submit

1. Please go to http://www.cybergrants.com/pfizer/Q1 and sign in. First-time users should click “Create your password”.
2. Select the following Primary Area of Interest: TTR Amyloidosis
3. Select the following Competitive Grant Program Name: 2024 RD G Raising Awareness & Promoting Timely Diagnosis of TTR Amyloidosis
4. Complete all required sections of the online application. See Appendix A for details.

Timing

Proposals must be completed in the CyberGrants system no later than Thursday, 2 May, 2024.

All applicants will be notified of the outcome of their application by email in September, 2024. Applicants may also be contacted to provide further clarification in order to support the review of this application.

If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. The agreement is expected to be signed by both parties within 2024 and without change.

Anticipated project start date for funded projects is early 2025.

Questions

If you have any questions regarding this RFP, or to discuss whether your project would be in scope, please contact Katie Kemper at Global Bridges (kemper.katherine@mayo.edu) or the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).
**OVERVIEW OF QUALITY IMPROVEMENT PROPOSAL REQUIREMENTS ON FOLLOWING PAGES**
# Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis
## Quality Improvement Proposal Requirements

Applications will be accepted via the online portal ([www.cybergrants.com/pfizer/QI](http://www.cybergrants.com/pfizer/QI)). All sections of your application will need to follow the character limits specified in the online application. *:

<table>
<thead>
<tr>
<th><strong>Goals and Objectives</strong></th>
<th>Briefly state the overall goal and objectives of the proposed project</th>
</tr>
</thead>
</table>
| **Assessment of Need for the Project** | Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.  
  
  Describe the source and method used to collect the data. Describe how the data were analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information. |
| **Target Audience** | Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population. |
| **Project Design and Methods** | Outline the proposed methodology and key stages or milestones of your planned approach. **Maximum project length is two years.** |
| **Innovation** |  
  - Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.  
  - Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project. |
| **Evaluation and Outcomes** | Describe how you will measure the success of your project. What measures and metrics will you use to evaluate the impact of the project? Describe your plan to capture baseline and end-of-project metrics and results. **Example** metrics include:  
  - Number of health care professionals trained  
  - Number of patients diagnosed with TTR Amyloidosis  
  - Number of patients receiving intervention |
<table>
<thead>
<tr>
<th>Anticipated Project Timeline</th>
<th>Provide an anticipated timeline for your project including project start/end dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional Information</td>
<td>Educational Sustainability: How will the results of the project be shared? How will the project support ongoing improvement in amyloidosis treatment and training?</td>
</tr>
<tr>
<td>Organizational Detail</td>
<td>Describe the mission, capability, and relevant previous activity of the applicant organization and how it will facilitate the project. Also include information about collaborating or project-partner organizations as applicable.</td>
</tr>
</tbody>
</table>
| Monetary Request              | Please indicate total monetary amount being requested for this project in United States Dollars (USD). While estimating your budget please keep the following items in mind:  
  o Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: Pfizer does not provide funding for capital equipment.  
  o Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please click here for details.  
  o It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription). |

*The online application also includes the fields noted above. The text in those fields should be the same text that is included in your Full Proposal document.*